Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial

• Published in: Blood Vol. 116; no. 21; p. 4024
• Main Authors: Lubbert, Michael, Suciu, Stefan, Platzbecker, Uwe, Giagounidis, Aristoteles A.N., Selleslag, Dominik, Labar, Boris, Germing, Ulrich, Kuendgen, Andrea, Salih, Helmut R., Muus, Petra, Rüter, Björn, Ganser, Arnold, Aul, Carlo, de Witte, Theo, Wijermans, Pierre W.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 19.11.2010

Abstract 4024▪ The hypomethylating agents 5-azacytidine (Vidaza) and 5-aza-2′-deoxycytidine (Decitabine, DAC) are active in different MDS subtypes. Compared to other response predictors to DAC, prior MDS duration has received only limited attention (1, 2), with conflicting results. Based on our find...